People Background Check
Find People:

Abhishek Datta224 Jamaicaway, Boston, MA 02130

Get Report
Known as:
Datta Abhishek

Abhishek Datta Phones & Addresses

224 Jamaicaway, Jamaica Plain, MA 02130

Roslindale, MA

680 Mix Ave, Hamden, CT 06514

680 Mix Ave #5H, Hamden, CT 06514

Chicago, IL

San Luis, CO

1926 W Harrison St APT 1002, Chicago, IL 60612

Show more

Mentions for Abhishek Datta

Abhishek Datta resumes & CV records

Resumes

Abhishek Datta Photo 30

Senior Director, Antibody Discovery And Engineering

Location:
48 Hemman St, Roslindale, MA 02131
Industry:
Research
Work:
Covidien since Nov 2009
PRINCIPAL RESEARCH SCIENTIST Harvard Medical School May 2005 - Dec 2009
Post doctoral research fellow University of Illinois at Chicago Jul 2004 - May 2005
Research Fellow
Education:
University of Illinois at Chicago 1998 - 2004
PhD, Biochemistry & Molecular genetics Madurai Kamaraj University 1996 - 1998
MS, Biotechnology Delhi University 1993 - 1996
BSc(H), Microbiolgy
Skills:
Molecular Biology, Biochemistry, Cell Biology, Immunology, Monoclonal Antibodies, Cell Based Assays, Cancer Research
Interests:
Science Editing
Editor (Part Time/Assignment Based)
American Journal Experts
Abhishek Datta Photo 31

Student At Muscat

Location:
Other
Industry:
Higher Education
Education:
muscat 1995 - 2010
Abhishek Datta Photo 32

Scientist At Biogen Idec

Location:
Greater Boston Area
Industry:
Research

Publications & IP owners

Us Patents

Ltbp Complex-Specific Inhibitors Of Tgfb And Uses Thereof

US Patent:
2022036, Nov 17, 2022
Filed:
May 17, 2022
Appl. No.:
17/746325
Inventors:
- Cambridge MA, US
Justin W. Jackson - Cambridge MA, US
George Coricor - Cambridge MA, US
Abhishek Datta - Boston MA, US
Stefan Wawersik - Westborough MA, US
Christopher Littlefield - Marblehead MA, US
Adam Fogel - Watertown MA, US
Caitlin Stein - Lebanon NH, US
Julia McCreary - Lebanon NH, US
Matthew Salotto - Lebanon NH, US
Frederick Streich, JR. - Newton MA, US
International Classification:
C07K 16/22
A61P 1/16
A61P 13/12
C07K 16/28
Abstract:
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ activation, and treating subjects suffering from TGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ inhibitor for a subject in need thereof are also provided.

Rgmc-Selective Inhibitors And Use Thereof

US Patent:
2021038, Dec 9, 2021
Filed:
Oct 23, 2019
Appl. No.:
17/285952
Inventors:
- Cambridge MA, US
Adriana Donovan - West Roxbury MA, US
Meghan McDonald - London, GB
Abhishek Datta - Boston MA, US
Allan Capili - Somerville MA, US
Kevin B. Dagbay - Brighton MA, US
Lorena Lerner - Newton MA, US
Leonard Ira Zon - Wellesley MA, US
Kevin Schutz - Lebanon NH, US
John Bukowski - Lebanon NH, US
Justin W. Jackson - Cambridge MA, US
International Classification:
C07K 16/18
A61P 7/06
Abstract:
Selective inhibitors of repulsive guidance molecule C (RGMc), are described. Related methods, including methods for making, as well as therapeutic use of these inhibitors in the treatment of disorders, such as anemia, are also provided.

Ltbp Complex-Specific Inhibitors Of Tgfb And Uses Thereof

US Patent:
2021004, Feb 18, 2021
Filed:
Aug 19, 2020
Appl. No.:
16/997438
Inventors:
- Cambridge MA, US
Justin W. Jackson - Cambridge MA, US
George Coricor - Cambridge MA, US
Abhishek Datta - Boston MA, US
Stefan Wawersik - Westborough MA, US
Christopher Littlefield - Marblehead MA, US
Adam Fogel - Watertown MA, US
Caitlin Stein - Lebanon NH, US
Julia McCreary - Lebanon NH, US
Matthew Salotto - Lebanon NH, US
Frederick Streich - Newton MA, US
International Classification:
C07K 16/22
C07K 16/28
A61P 13/12
A61P 1/16
Abstract:
Disclosed herein are inhibitors, such as antibodies, and antigen-binding portions thereof, that selectively bind complexes of LTBP1-TGFβ and/or LTBP3-TGFβ. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ activation, and treating subjects suffering from TGFβ-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ inhibitor for a subject in need thereof are also provided.

Ltbp Complex-Specific Inhibitors Of Tgf-Beta 1 And Uses Thereof

US Patent:
2020023, Jul 23, 2020
Filed:
Jul 27, 2018
Appl. No.:
16/634336
Inventors:
- Cambridge MA, US
Christopher Littlefield - Marblehead MA, US
Gregory J. Carven - Maynard MA, US
Abhishek Datta - Boston MA, US
International Classification:
C07K 16/28
C07K 16/22
Abstract:
Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGFβ1 and/or LTBP3-TGFβ1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGFβ1 activation, and treating subjects suffering from TGFβ1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGFβ1 inhibitor for a subject in need thereof are also provided.

Lrrc33 Inhibitors And Use Thereof

US Patent:
2020018, Jun 11, 2020
Filed:
May 9, 2018
Appl. No.:
16/611029
Inventors:
- Cambridge MA, US
Gregory J. Carven - Maynard MA, US
Stefan Wawersik - Westborough MA, US
Thomas Schurpf - Cambridge MA, US
Constance Martin - Arlington MA, US
Abhishek Datta - Boston MA, US
Mark Allen Farmer - North Reading MA, US
International Classification:
C07K 16/22
A61P 35/04
A61P 35/02
Abstract:
Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.

Isoform-Specific, Context-Permissive Tgfb1 Inhibitors And Use Thereof

US Patent:
2019020, Jul 11, 2019
Filed:
Mar 22, 2019
Appl. No.:
16/361486
Inventors:
- Cambridge MA, US
Abhishek Datta - Boston MA, US
Gregory J. Carven - Maynard MA, US
Constance Martin - Arlington MA, US
Ashish Kalra - Belmont MA, US
Kimberly Long - Boston MA, US
Alan Buckler - Arlington MA, US
International Classification:
A61K 39/395
C07K 16/22
G01N 33/574
A61P 35/04
Abstract:
Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGFβ1 in the treatment of disease that involve TGFβ1 dysregulation.

Tgfbeta1-Binding Immunoglobulins And Use Thereof

US Patent:
2019007, Mar 7, 2019
Filed:
Mar 10, 2017
Appl. No.:
16/083637
Inventors:
- Cambridge MA, US
Gregory J. Carven - Maynard MA, US
Abhishek Datta - Boston MA, US
Kimberly Long - Boston MA, US
International Classification:
C07K 16/22
A61K 39/395
A61P 13/12
A61P 35/00
A61P 21/00
Abstract:
Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGFβ1, LTBP1-TGFβ1, LTBP3-TGFβ1, and/or LRRC33-TGFβ1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGFβ1 activity, and treating subjects suffering from TGFβ1-related disorders, such as cancer and fibrosis.

Isoform-Specific, Context-Permissive Tgfb1 Inhibitors And Use Thereof

US Patent:
2018020, Jul 26, 2018
Filed:
Jan 5, 2018
Appl. No.:
15/863564
Inventors:
- Cambridge MA, US
Abhishek Datta - Boston MA, US
Gregory J. Carven - Maynard MA, US
Constance Martin - Arlington MA, US
Ashish Kalra - Belmont MA, US
Kimberly Long - Boston MA, US
Alan Buckler - Arlington MA, US
International Classification:
A61K 39/395
C07K 16/22
G01N 33/574
A61P 35/04
Abstract:
Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGFβ1 in the treatment of disease that involve TGFβ1 dysregulation.

Possible Relatives

Debasish Datta  Abhijit S Datta  Indrani I Datta  Kaushik Datta  Manjira Datta  Neelam Datta  Neeraj Datta  Abhishek Singh  Abhishek P Patel  Abhishek N Prasad 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.